Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance

Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033Trade
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Trade

Price performance (Past 24H)

Key statistics

Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $64.51 (market cap $394.18M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 149× Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 for 63 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.

SLVOTAK
Market Cap
$394.18M$58.74B
Volume
84,8433,110,994
Sector
Income / Options OverlayHealth
52-Week High
$107.41$19.05
52-Week Low
$61.81$13.23
Typical Hold Time
63 Days1 Days
Enterprise Value
—$86.65B
Dividend Yield
—3.33%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033

SLVO is trading at $63.56, down 2.67% amid bearish technical signals. The stock recently crossed below its 50-day moving average of $73.20, indicating weakening momentum. Recent news highlights silver price declines and technical breakdowns as key drivers. Technical indicators show a bearish moving average signal with neutral oscillators, while RSI levels near 29 suggest potential oversold conditions.

The outlook remains cautious with silver market volatility and dollar strength creating headwinds. Investment opportunity exists if oversold conditions lead to reversal, but risks include continued commodity pressure and technical breakdown. The stock faces resistance at $66-$67 levels with support around $64-$65.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SLVO
100% Buy0% Sell
Avg holding period · 63 Days
TAK

No sentiment data available yet.

Top news

Latest headlines on both assets

About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033

SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.

Read more on SLVO →

About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.

Read more on TAK →